Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Labcorp (LH) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDiagnostics & ResearchLH

Closing price · Nov 19, 2026 $369.02 -0.5% on the day · +43.1% over 12 months 52-week range $248.55 – $372.46
Get LH alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling10last 12 months
Reported sales$11.8M15 of 25 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 27, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Amy B. Summy, Evp, Chief Marketing Officer sold 365 shares at $372.58 ($136K).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Sale (code S)

Read the original SEC filing ↗All LH insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

LH insider transactions (Form 4)

Open-market purchases and sales. 133 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Amy B. SummyEvp, Chief Marketing Officer Sell 3656,590 held (−5%) $372.58 $136K -1.0% —
Nov 12SEC Brian J. CaveneyEvp, Pres Of Bls, Cmo & Cso Sell 2,00034,562 held (−5%) $372.04 $744K -0.8% —
Nov 5SEC Bryan T. VaughnPresident Sell Plan 3066,845 held (−4%) $353.70 $108K +4.3% —
Nov 3SEC Richelle P. ParhamDirector Sell 1,0782,288 held (−32%) $361.22 $389K +2.2% —
Aug 18SEC Kerrii B. AndersonDirector Sell Plan 3,0006,563 held (−31%) $318.02 $954K +16.0% —
Aug 12SEC Adam H. SchechterCEO, President Sell Plan 4,669102,565 held (−4%) $320.37 $1.5M +15.2% —
Aug 6SEC Amy B. SummyEvp, Chief Marketing Officer Sell 9246,956 held (−12%) $306.74 $283K +20.3% —
Aug 5SEC Peter J. WilkinsonSvp, Chief Accounting Officer Sell 1,3381,770 held (−43%) $309.23 $414K +19.3% —
Aug 5SEC Peter J. WilkinsonSvp, Chief Accounting Officer Sell 821,770 held (−4%) $309.22 $25K +19.3% —
Jul 6SEC Bryan T. VaughnPresident Sell Plan 2346,746 held (−3%) $286.19 $67K +28.9% —
Jul 6SEC Kathryn W. KyleGeneral Counsel Sell Plan 923,904 held (−2%) $286.19 $26K +28.9% —
Jun 10SEC Kathryn W. KyleGeneral Counsel Sell Plan 7623,813 held (−17%) $263.89 $201K +39.8% —
May 13SEC Adam H. SchechterCEO, President Sell Plan 5,903107,234 held (−5%) $254.50 $1.5M +45.0% —
Mar 30SEC Peter J. WilkinsonSvp, Chief Accounting Officer Sell Plan 1,6331,852 held (−47%) $267.05 $436K +38.2% —
Mar 30SEC Jonathan C. MeltzerEvp, Operations Sell Plan 8393,620 held (−19%) $267.05 $224K +38.2% —
Mar 5SEC Adam H. SchechterCEO, President Sell 8,70580,773 held (−10%) $279.96 $2.4M +31.8% —
Mar 3SEC Der Vaart Sandra D. VanEvp, Corporate Affairs Sell 5482,579 held (−18%) $284.91 $156K +29.5% —
Feb 26SEC Brian J. CaveneyEvp, Pres Of Ed, Cmo & Cso Sell 1,50030,107 held (−5%) $286.31 $429K +28.9% —
Feb 23SEC Peter J. WilkinsonSvp, Chief Accounting Officer Sell Plan 6661,852 held (−26%) $277.94 $185K +32.8% —
Feb 13SEC Adam H. SchechterCEO, President Sell Plan 5,27387,343 held (−6%) $284.38 $1.5M +29.8% —
Feb 13SEC Jonathan C. MeltzerEvp, Operations Sell Plan 872,782 held (−3%) $290.42 $25K +27.1% —
Feb 12SEC Jonathan C. MeltzerEvp, Operations Sell Plan 912,696 held (−3%) $276.79 $25K +33.3% —
Feb 10SEC Jonathan C. MeltzerEvp, Operations Sell Plan 882,869 held (−3%) $275.53 $24K +33.9% —
Nov 13SEC Adam H. SchechterCEO, President Sell Plan 5,74587,574 held (−6%) $262.75 $1.5M +40.4% —
Nov 4SEC Richelle P. ParhamDirector Sell 7,0092,469 held (−74%) $254.28 $1.8M +45.1% —
Historical context

Similar past setups: not applicable. LH has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with LH in the Research Lab

LH has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

LH closeInsider buyInsider sale
200250300350400DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-17EEarnings release filed 2026-04-30EEarnings release filed 2026-07-30EEarnings release filed 2026-10-28Sold $24,247 on 2026-02-09 · Jonathan C. MeltzerSold $25,188 on 2026-02-10 · Jonathan C. MeltzerSold $25,267 on 2026-02-12 · Jonathan C. MeltzerSold $93,298 on 2026-07-02 · Bryan T. Vaughn, Kathryn W. KyleSold $108,232 on 2026-11-03 · Bryan T. VaughnSold $135,992 on 2026-11-16 · Amy B. SummySold $156,000 on 2026-02-27 · Der Vaart Sandra D. VanSold $185,108 on 2026-02-19 · Peter J. WilkinsonSold $201,084 on 2026-06-08 · Kathryn W. KyleSold $283,428 on 2026-08-04 · Amy B. SummySold $389,395 on 2026-10-30 · Richelle P. ParhamSold $429,458 on 2026-02-24 · Brian J. CaveneySold $439,107 on 2026-08-03 · Peter J. WilkinsonSold $660,148 on 2026-03-27 · Jonathan C. Meltzer, Peter J. WilkinsonSold $744,080 on 2026-11-10 · Brian J. CaveneySold $954,060 on 2026-08-17 · Kerrii B. AndersonSold $1,495,808 on 2026-08-11 · Adam H. SchechterSold $1,499,536 on 2026-02-11 · Adam H. SchechterSold $1,502,314 on 2026-05-11 · Adam H. SchechterSold $2,437,047 on 2026-03-03 · Adam H. Schechter
Bought, 12 months$0
Sold, 12 months$11.8M
Insiders buying0
Insiders selling10

Labcorp insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $11.8M of LH stock on the open market; P/E 25.5 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

LH insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $3.3M sold (2 trades)Q4 2025Q1 2026: $5.4M sold (10 trades)Q1 2026Q2 2026: $1.7M sold (2 trades)Q2 2026Q3 2026: $3.3M sold (7 trades)Q3 2026Q4 2026: $1.4M sold (4 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$1.4M4
Q3 2026—0$3.3M7
Q2 2026—0$1.7M2
Q1 2026—0$5.4M10
Q4 2025—0$3.3M2

Valuation, profit and volume

P/E (trailing)25.5Sector median 25.0
Market value$25.03BDiagnostics & Research
Profit margin7.0%Revenue growth +5.8%
Volume vs. 50-day0.7×Last 5 sessions

Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Labcorp insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $11.8M. 15 of 25 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

LH earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 28, 2026 +5.0% None +11.2%S&P -0.0% pending
Jul 30, 2026 +11.4% Sold $93K +0.7%S&P +2.4% +8.6%
Apr 30, 2026 -4.4% None -0.5%S&P +1.3% +1.9%
Feb 17, 2026 +4.8% Sold $1.6M -1.4%S&P +0.7% -5.4%
Oct 28, 2025 -0.8% None -10.0%S&P +0.3% +8.6%
Jul 24, 2025 -2.7% None +5.8%S&P +0.5% +5.0%
Apr 29, 2025 +3.7% None +5.0%S&P +0.7% +3.6%
Feb 6, 2025 +2.5% None -1.5%S&P -0.6% +3.0%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

LH short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 44% of volume sold short2026-08-27: 41% of volume sold short2026-08-28: 52% of volume sold short2026-08-31: 57% of volume sold short2026-09-01: 63% of volume sold short2026-09-02: 48% of volume sold short2026-09-03: 63% of volume sold short2026-09-04: 54% of volume sold short2026-09-08: 51% of volume sold short2026-09-09: 31% of volume sold short2026-09-10: 60% of volume sold short2026-09-11: 44% of volume sold short2026-09-14: 54% of volume sold short2026-09-15: 70% of volume sold short2026-09-16: 75% of volume sold short2026-09-17: 57% of volume sold short2026-09-18: 56% of volume sold short2026-09-21: 46% of volume sold short2026-09-22: 31% of volume sold short2026-09-23: 35% of volume sold short2026-09-24: 39% of volume sold short2026-09-25: 58% of volume sold short2026-09-28: 62% of volume sold short2026-09-29: 63% of volume sold short2026-09-30: 49% of volume sold short2026-10-01: 33% of volume sold short2026-10-02: 39% of volume sold short2026-10-05: 58% of volume sold short2026-10-06: 44% of volume sold short2026-10-07: 53% of volume sold short2026-10-08: 42% of volume sold short2026-10-09: 32% of volume sold short2026-10-12: 45% of volume sold short2026-10-13: 45% of volume sold short2026-10-14: 51% of volume sold short2026-10-15: 55% of volume sold short2026-10-16: 47% of volume sold short2026-10-19: 38% of volume sold short2026-10-20: 47% of volume sold short2026-10-21: 50% of volume sold short2026-10-22: 60% of volume sold short2026-10-23: 54% of volume sold short2026-10-26: 31% of volume sold short2026-10-27: 38% of volume sold short2026-10-28: 51% of volume sold short2026-10-29: 46% of volume sold short2026-10-30: 51% of volume sold short2026-11-02: 29% of volume sold short2026-11-03: 42% of volume sold short2026-11-04: 61% of volume sold short2026-11-05: 64% of volume sold short2026-11-06: 63% of volume sold short2026-11-09: 42% of volume sold short2026-11-10: 43% of volume sold short2026-11-11: 61% of volume sold short2026-11-12: 68% of volume sold short2026-11-13: 41% of volume sold short2026-11-16: 55% of volume sold short2026-11-17: 68% of volume sold short2026-11-18: 51% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 51%20-day average: 50%Prior 2 months: 49%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded LH

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +40.4%

Insiders at Labcorp

InsiderBoughtSoldLast filingPast buys beat S&PScore
Adam H. SchechterCEO, President — $8.4M Aug 12, 2026 — —
Richelle P. ParhamDirector — $2.2M Nov 3, 2026 — —
Brian J. CaveneyEvp, Pres Of Bls, Cmo & Cso — $1.2M Nov 12, 2026 — —
Peter J. WilkinsonSvp, Chief Accounting Officer — $1.1M Aug 5, 2026 — —
Kerrii B. AndersonDirector — $954K Aug 18, 2026 0 of 2 —
Amy B. SummyEvp, Chief Marketing Officer — $419K Nov 18, 2026 — —
Jonathan C. MeltzerEvp, Operations — $299K Mar 30, 2026 — —
Kathryn W. KyleGeneral Counsel — $227K Jul 6, 2026 — —
Bryan T. VaughnPresident — $175K Nov 5, 2026 — —
Der Vaart Sandra D. VanEvp, Corporate Affairs — $156K Mar 30, 2026 — —
Akinbolade OyegunwaCTO — — Nov 3, 2026 — —
Mark S. SchroederCOO — — Mar 30, 2026 — —
Anita Z. GrahamEvp, Chro — — Mar 30, 2026 — —
Megan D. BaileyEvp, Pres, Central Labs & Intl — — Mar 30, 2026 — —
Julia Aijun WangCFO — — Feb 13, 2026 — —
Jeffrey A. DavisDirector — — Feb 13, 2026 — —
Kirsten Marie KliphouseDirector — — Feb 13, 2026 — —
Garheng KongDirector — — Feb 13, 2026 — —
Peter M. NeupertDirector — — Feb 13, 2026 — —
Kathryn E. WengelDirector — — Feb 13, 2026 — —
Paul RothmanDirector — — Feb 13, 2026 — —

Board links: companies that share insiders with LH

Directors and executives who filed Form 4s for LH and another company in the last 12 months.

See the map →
  • ADPTAdaptive Biotechnologies Peter M. Neupert Director here · Director at ADPT · latest filing Aug 19, 2026
  • BBYBest Buy Richelle P. Parham Director here · Director at BBY · latest filing Nov 3, 2026
  • DVADaVita Adam H. Schechter CEO, President here · Director at DVA · latest filing Nov 17, 2026
  • FDXFFedEx Freight Jeffrey A. Davis Director here · Director at FDXF · latest filing Jul 1, 2026
  • GPNGlobal Payments Kirsten Marie Kliphouse Director here · Director at GPN · latest filing May 4, 2026
  • JNJJohnson & Johnson Kathryn E. Wengel Director here · Evp, Chief To And Risk Officer at JNJ · latest filing Jun 12, 2026
  • SHWSherwin-Williams Kerrii B. Anderson Director here · Director at SHW · latest filing Oct 6, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

LH stock: common questions

Are Labcorp insiders buying LH stock?

No. No Labcorp insider reported an open-market purchase of LH in the past 12 months.

Are Labcorp insiders selling LH stock?

10 insiders reported sales worth $11.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is LH's P/E ratio?

LH trades at about 25.5 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is LH's 52-week range?

Over the past year LH has traded between $248.55 and $372.46. It last closed at $369.02 on Nov 19, 2026.